Mutations of the p16 gene product are rare in prostate cancer

Prostate

Volumn 30, Issue 3, 1997, Pages 188-194

  Gaddipati, Jaya P ^a,b   McLeod, David G ^a,b   Sesterhenn, Isabell A ^c   Hussussian, Christopher J ^d   Tong, Yue Ao ^a,b   Seth, Prem ^e   Dracopoli, Nicholas C ^d   Moul, Judd W ^a,b   Srivastava, Shiv ^a,b  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

^c ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

^d NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

Author keywords

microsatellite; p16; polymerase chain reaction; prostate cancer; single strand conformation polymorphism

Indexed keywords

ARTICLE; CARCINOGENESIS; CODON; DNA DETERMINATION; HUMAN; HUMAN CELL; MALE; MISSENSE MUTATION; PRIORITY JOURNAL; PROSTATE CANCER; SINGLE STRAND CONFORMATION POLYMORPHISM;

BLOTTING, NORTHERN; BLOTTING, SOUTHERN; CARRIER PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA PROBES; DNA, NEOPLASM; GENES, TUMOR SUPPRESSOR; HUMANS; MALE; MICROSATELLITE REPEATS; MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROSTATIC NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0030892851     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(19970215)30:3<188::AID-PROS7>3.0.CO;2-I     Document Type: Article

References (32)

1. Boring CC, Squires TS, Tong T: Cancer statistics; 1994. CA 43:7-26, 1994.
2. Weinberg RA: The molecular basis of oncogenes and tumor suppressor genes. Ann NY Acad Sci 758:331-338, 1995.
3. Isaacs WB, Bova GS, Morton RA, Bussemakers MJG, Brooks JD, Ewing CM: Molecular biology of prostate cancer. Semin Oncol 21:514-521, 1994.
4. Bookstein R: Tumor suppressor genes in prostate oncogenesis. J Cell Biochem (suppl) 19:217-233, 1994.
5. Moul JW, Gaddipati JP, Srivastava S: Molecular biology of prostate cancer: oncogenes and tumor suppressor genes. In "Current Clinical Oncology: Prostate Cancer." New York: Wiley- Liss, Inc., 1994, pp 19-46.
6. Kamb A, Gruis N, Weaver-Feldhaus J, Liu Q, Harshman K, Tavrigian SV, Stockert E, Day RS III, Johnson BE, Skolnick MH: A cell cycle regulator potentially involved in genesis of many tumor types. Science 264: 436-440, 1994.
7. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA: Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368: 753-756, 1994.
8. Hussussian CJ, Struewing JP, Goldstein AM, Higgins PAT, Ally DS, Sheahan MD, Clark WH Jr, Tucker MA, Dracopoli NC: Germline p16 mutations in familial melanoma. Nat Genet 8:15-21, 1994.
9. Caldas C, Hahn SA, da Costa LT, Redston MS, Schutte M, Seymour AB, Weinstein CL, Hruban RH, Yeo CJ, Kern SE: Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet 8:27-32, 1994.
10. Hayashi N, Sugimoto Y, Tsuchiya E, Ogawa M, Nakamura Y: Somatic mutations of the MTS (multiple tumor suppressor) 1/CDK4I (cyclin-dependent kinase-4 inhibitor) gene in human primary non-small cell lung carcinomas. Biochem Biophys Res Commun 202:1426-1430, 1994.
11. Serrano M, Hannon GJ, Beach D: A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 266:704-707, 1993.
12. He J, Allen JR, Collins P, Allalunis-Turner MJ, Godbout R, Day RS, James C: CDK4 amplification is an alternative mechanism to p16 gene homozygous deletion in glioma cell lines. Cancer Res 54:5804-5807, 1994.
13. Schmidt EE, Ichimura K, Reifenberger G, Collins P: CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Cancer Res 54:6321-6324, 1994.
14. Gingrich JR, Tucker JA, Walther PJ, Day JW, Poulton SHM, Webb KS: Establishment and characterization of a new human prostatic carcinoma cell line (DuPro-1). J Urol 146:915-919, 1991.
15. Ware JL, Paulson DF, Mickey GH, Webb KS: Spontaneous metastasis of cells of the human prostate carcinoma cell line PC-3 in athymic nude mice. J Urol 128: 1064-1067, 1982.
16. Heidenberg HB, Sesterhenn IA, Gaddipati JP, Weghorst CM, Buzard GS, Moul JW, Srivastava S: Alteration of the tumor suppressor gene p53 in a high fraction of hormone refractory prostate cancer. J Urol 154:414-421, 1995.
17. Hanks SK: Homology probing: identification of cDNA clones encoding members of the protein-serine kinase family. Proc Natl Acad Sci USA 84:388-392, 1987.
18. Tso JY, Sun X, Kao T, Reece KS, Wu R: Isolation and characterization of rat and human glyceraldehyde-3-phosphate dehydrogenase cDNAs: genomic complexity and molecular evolution of the gene. Nucleic Acids Res 13:2485-2502, 1985.
19. Weissenbach J, Gyapay G, Dib C, Vignal A, Morisette J, Milasseau P, Vaysseix G, Lathrop M: A second-generation linkage map of the human genome. Nature 359: 794-801, 1992.
20. Kwiatkowski D, Diaz MO: Dinucleotide repeat polymorphism at the IFNA locus (9p22). Hum Mol Genet 1:658, 1992.
21. Litt M, Hague X, Sharma V: Shadow bands seen when typing polymorphic dinucleotide repeats: some causes and cures. Biotechniques 15:280-284, 1993.
22. ink4) in human breast carcinomas. Cancer Res 54: 5262-5264, 1994.
23. Ueki K, Rubio MP, Ramesh V, Corea K, Rutter JL, Deimling AV, Buckler AJ, Gusella JF, Louis DN: MTS1/ CDKN2 gene mutations are rare in primary human astrocytomas with allelic loss of chromosome. Hum Mol Genet 3:1841-1845, 1994.
24. Komiya A, Suzuki H, Aida S, Yatani R, Shimazaki J: Mutational analysis of CDKN2 (CDK4I/MTS1) gene in tissues and cell lines of human prostate cancer. Jpn J Cancer Res 86:622-625, 1995.
25. Cairns P, Polascik TJ, Eby Y, Tokino K, Califano J, Merlo A, Mao L, Herath J, Jenkins R, Westra W, Rutter JL, Buckler A, Gabrielson E, Tockman M, Cho KR, Hedrick L, Bova GS, Isaacs W, Koch W, Schwab D, Sidransky D: Frequency of homozygous deletion at p16/ CDKN2 in primary human tumours. Nat Genet 11:210-212, 1995.
26. INK4a tumor suppressor protein. Cancer Res 55:2503-2506, 1995.
27. Liu Q, Neuhausen S, McClure M, Frye C, Weaver-Feldhaus J, Gruis NA, Eddington K, Allalunis-Turner MJ, Skolnick MH, Fujimura FK, Kamb A: CDKN2 (MTS1) tumor suppressor gene mutations in human tumor cell lines. Oncogene 10:1061-1067, 1995.
28. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, Baylin SB, Sidransky D: 5′ CpG island methylation is associated with transcriptional silencing of the tumor suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1:686-692, 1995.
29. Stone S, Jiang P, Dayananth P, Tatigian SV, Katcher H, Parry D, Peters G, Kamb A: Complex structure and regulation of the p16 (MTS1) locus. Cancer Res 55: 2988-2994, 1995.
30. Herman JG, Merlo A, Mao L, Lapidus RG, Issa JJ, Davidson NE, Sidransky D, Baylin SB: Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 55:4525-4530, 1995.
31. Navone NM, Troncoso P, Pisters LL, Goodrow TL, Palmer JL, Nichols WW, von Eschenbach AC, Conti CJ: p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J Natl Cancer Inst 85:1657-1669, 1993.
32. Aprikian AG, Sarkis AS, Fair WR, Zhang ZF, Fuks Z, Cordon-Crdo C: Immunohistochemical determination of p53 protein nuclear accumulation in prostatic adenocarcinoma. J Urol 151:1276-1280, 1994.